{"filing":{"accession_number":"0001193125-26-349160","cik":"0001650648","ticker":"FDMT","company_name":"4D Molecular Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"fdmt-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-20260813.htm"},"events":[{"id":27586,"run_id":25153,"accession_number":"0001193125-26-349160","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"4DMT disclosed its Q2 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes a complete Statements of Operations showing revenue of $3.8 million, R\u0026D expenses of $68.3 million, and a net loss of $72.9 million for the three months ended June 30, 2026, along with balance sheet data and cash position information. This is a standard quarterly earnings release for a public biotechnology company.","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29174,"accession_number":"0001193125-26-349160","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"4DMT disclosed its Q2 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes a complete Statements of Operations showing revenue of $3.8 million, R\u0026D expenses of $68.3 million, and a net loss of $72.9 million for the three months ended June 30, 2026, along with balance sheet data and cash position information. This is a standard quarterly earnings release for a public biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:40.570768+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29174,"accession_number":"0001193125-26-349160","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"4DMT disclosed its Q2 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The filing includes a complete Statements of Operations showing revenue of $3.8 million, R\u0026D expenses of $68.3 million, and a net loss of $72.9 million for the three months ended June 30, 2026, along with balance sheet data and cash position information. This is a standard quarterly earnings release for a public biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:40.570768+00:00","company_name":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","filing_date":"2026-08-13"}]}